547.74
price up icon2.40%   12.83
after-market 시간 외 거래: 547.00 -0.74 -0.14%
loading
전일 마감가:
$534.91
열려 있는:
$533.66
하루 거래량:
817.89K
Relative Volume:
0.64
시가총액:
$56.52B
수익:
$14.09B
순이익/손실:
$4.50B
주가수익비율:
13.94
EPS:
39.28
순현금흐름:
$2.96B
1주 성능:
+5.28%
1개월 성능:
+11.60%
6개월 성능:
-23.41%
1년 성능:
-47.57%
1일 변동 폭
Value
$529.69
$551.50
1주일 범위
Value
$514.79
$551.50
52주 변동 폭
Value
$476.49
$1,211.20

리제네론 파마슈티컬스 Stock (REGN) Company Profile

Name
명칭
Regeneron Pharmaceuticals Inc
Name
전화
(914) 847-7000
Name
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
직원
15,158
Name
트위터
@regeneron
Name
다음 수익 날짜
2025-02-04
Name
최신 SEC 제출 서류
Name
REGN's Discussions on Twitter

REGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-30 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2025-05-30 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-05-14 업그레이드 Citigroup Neutral → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-02-05 업그레이드 Leerink Partners Market Perform → Outperform
2025-01-16 다운그레이드 UBS Buy → Neutral
2024-12-10 재개 BofA Securities Underperform
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Neutral
2024-09-24 다운그레이드 Leerink Partners Outperform → Market Perform
2024-03-12 개시 Bernstein Outperform
2024-01-12 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-11-03 업그레이드 Raymond James Mkt Perform → Outperform
2023-08-21 업그레이드 Canaccord Genuity Hold → Buy
2023-08-21 재확인 Oppenheimer Perform
2023-06-28 다운그레이드 Canaccord Genuity Buy → Hold
2023-03-27 업그레이드 SVB Securities Market Perform → Outperform
2023-03-24 업그레이드 Jefferies Hold → Buy
2023-03-23 업그레이드 Raymond James Underperform → Mkt Perform
2023-01-30 업그레이드 Cowen Market Perform → Outperform
2023-01-20 업그레이드 JP Morgan Neutral → Overweight
2022-10-26 다운그레이드 Raymond James Mkt Perform → Underperform
2022-10-17 다운그레이드 Evercore ISI Outperform → In-line
2022-09-09 업그레이드 Jefferies Underperform → Hold
2022-09-09 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-07-25 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-06-06 개시 Jefferies Underperform
2022-05-23 개시 SVB Leerink Outperform
2022-01-05 다운그레이드 BofA Securities Neutral → Underperform
2022-01-03 업그레이드 Bernstein Mkt Perform → Outperform
2021-12-15 다운그레이드 Bernstein Outperform → Mkt Perform
2021-12-09 재개 Wells Fargo Overweight
2021-12-07 재개 Cowen Market Perform
2021-12-06 개시 Goldman Buy
2021-11-19 재개 BMO Capital Markets Outperform
2021-11-05 다운그레이드 The Benchmark Company Buy → Hold
2021-06-29 개시 H.C. Wainwright Buy
2021-01-25 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-01-13 업그레이드 The Benchmark Company Hold → Buy
2021-01-08 업그레이드 Citigroup Neutral → Buy
2020-10-05 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-08-20 다운그레이드 The Benchmark Company Buy → Hold
2020-07-09 업그레이드 SunTrust Hold → Buy
2020-05-26 업그레이드 Wells Fargo Equal Weight → Overweight
2020-04-28 다운그레이드 Citigroup Buy → Neutral
2020-04-17 업그레이드 The Benchmark Company Hold → Buy
2020-04-08 개시 The Benchmark Company Hold
2020-03-31 개시 Wolfe Research Peer Perform
2020-02-27 개시 Barclays Overweight
2020-02-26 업그레이드 Canaccord Genuity Hold → Buy
2020-02-26 다운그레이드 Robert W. Baird Outperform → Neutral
2020-02-25 업그레이드 Jefferies Hold → Buy
2020-02-11 업그레이드 Argus Hold → Buy
2019-12-24 개시 Raymond James Mkt Perform
2019-12-16 다운그레이드 Evercore ISI Outperform → In-line
2019-12-13 업그레이드 Credit Suisse Neutral → Outperform
2019-11-12 개시 SunTrust Hold
2019-11-07 업그레이드 Citigroup Neutral → Buy
2019-10-17 재개 BofA/Merrill Neutral
2019-09-23 업그레이드 Guggenheim Neutral → Buy
모두보기

리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스

pulisher
Jun 18, 2025

Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 20 - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Regeneron Shareholders Approve Key Proposals at 2025 Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Factory Mutual Insurance Co. Buys 8,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

Regeneron Steps Back, TTAM Aims To Reclaim 23andMe - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron (REGN) Exits 23andMe Bidding War - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Breakthroughs in Uveitis Treatment Market Drive Global Demand - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

23andme founder-led group outbids Regeneron for company - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Fifth Third Bancorp Sells 952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki overcomes Regeneron in 23andMe assets battle - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki’s Nonprofit Tops Bid for 23andMe Assets - Contract Pharma

Jun 16, 2025
pulisher
Jun 16, 2025

Patient Data Revolution: New Blockchain Platform Challenges Regeneron's $600M 23andMe Data Grab - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

BDF Gestion Has $2.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Warther Private Wealth LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

RMR Wealth Builders Acquires Shares of 2,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Osprey Private Wealth LLC Makes New $2.24 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Pallas Capital Advisors LLC Invests $426,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi: positive data in chronic rhinosinusitis - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Leerink Partnrs Issues Negative Forecast for REGN Earnings - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NorthCrest Asset Manangement LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Sanofi, Regeneron Report Encouraging Results from Head-to-head Respiratory Study - MarketScreener

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron (REGN) and Sanofi's Dupixent Shows Superior Results in Key Phase 4 Trial | REGN Stock News - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial for Nasal Polyps | REGN Stock News - Stock Titan

Jun 15, 2025
pulisher
Jun 15, 2025

Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Wedmont Private Capital Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com

Jun 14, 2025

리제네론 파마슈티컬스 (REGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

리제네론 파마슈티컬스 주식 (REGN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
McCourt Marion
EVP Commercial
Nov 01 '24
Option Exercise
381.40
1,000
381,400
13,931
McCourt Marion
EVP Commercial
Nov 01 '24
Sale
844.61
1,000
844,610
12,931
$329.77
price up icon 2.39%
$545.11
price up icon 0.49%
biotechnology ONC
$244.32
price down icon 0.34%
$108.26
price up icon 0.70%
$98.24
price up icon 0.64%
자본화:     |  볼륨(24시간):